Dr. Ann Moyer is an Associate Professor of Laboratory Medicine and Pathology as well as Assistant Professor of Pharmacology at the Mayo Clinic where she is involved in clinical laboratory testing for pharmacogenomics and hereditary disorders. She is the Vice Chair for Quality of the Division of Laboratory Genetics and Genomics. Her research interests include pharmacogenomics (particularly improvements in clinical laboratory testing and impact of rare variants), complement system genetics, and primary immunodeficiency genetics. Dr. Moyer has authored over 80 peer-reviewed manuscripts. After graduation from the University of Wisconsin-Platteville, Dr. Moyer completed the MD/PhD program, pathology residency, and molecular genetic pathology fellowship at Mayo Clinic. Her PhD thesis work focused on the pharmacogenomics of phase II drug metabolizing enzymes under the mentorship of Dr. Richard Weinshilboum.
Pharmacogenomics Laboratory Best Practices and Navigating Regulatory Requirements
This presentation will cover considerations and resources for developing and running a clinical test, including a brief discussion of the regulatory framework.
Mary Relling, St. Jude
Pharmacists have long recognized that using unique patient characteristics to guide pharmacotherapy decision-making can improve drug response and mitigate drug-associated risks. Age, weight, and dietary habits were among the first patient-specific characteristics used to individualize pharmacotherapy. As technologies advanced, analytic tools that measure surrogate markers of liver and renal function, together with drug concentrations in biological fluids, were adopted to optimize therapeutic regimens. Cutting-edge genomic technologies are now being integrated into patient care for the selection of targeted therapies and identification of those at increased risk of poor pharmacotherapy outcomes. We’re excited to bring together experts who are advancing pharmacogenomics at scale through cutting edge clinical implementation, research, and education.